Stephanie Egge, M.D.

  • Assistant Professor of Medicine, Division of Infectious Diseases, School of Medicine


Dr. Egge is an Infectious Diseases provider in the OHSU Division of Infectious Diseases.  She received her medical degree from Texas Tech University Health Sciences Center in Lubbock, TX after which she completed an internal medicine residency at Louisiana State Health Sciences Center/Oschner Health System in Shreveport, LA (2017-2020). She completed a combined immunocompromised infectious diseases fellowship at University of Texas Houston/MD Anderson Cancer Center (2020-2022). She spent more than half of her clinical training treating immunocompromised patients with hematologic malignancies, bone marrow transplant, and/or solid organ malignancies, and her interest in the immunocompromised host prompted her research ambitions: understanding the pathogenicity and antimicrobial resistance patterns of the gram-negative bacteria Pseudomonas aeruginosa.

From 2020-2023, Dr. Egge worked under the clinical and research mentorship of Drs. William R. Miller and Cesar A. Arias (Houston Methodist Hospita/Weill-Cornell Medical College) studying the resistance mechanisms in pathogenic enterococcal and pseudomonal species. Through the Training Program for Antimicrobial Resistance (TPAMR AI141349), she completed a dedicated T32 post-doctoral research fellowship year at Houston Methodist Hospital where she studied the impact of pseudomonal derived cephalosporinases, exogenous beta-lactamase, and iron-dependent porin transport systems on the anti-pseudomonal activity of novel agents such as ceftolozane-tazobactam and cefiderocol. During that time, she worked both as clinical staff treating general infectious diseases patients as well as solid organ and bone marrow transplant patients. In 2023, she relocated to Portland, OR where she is continuing to work under the primary mentorship of Dr. Morgan Hakki investigating mechanisms of P. aeruginosa resistance, the role of host factors, and clinical outcomes of P. aeruginosa colonization and infection. Other professional interests include oral approaches to treating Gram-positive bacteremia and eliminating healthcare and community stigmas of sexually transmitted and IV drug use-related illness.

In her spare time, Dr. Egge enjoys traveling, hiking, running, eating good food, and spending time with her family, including her senior Weimaraner-Lab mutt Kashmir.

Education and training

    • B.S., 2012, University of Washington (Seattle)
    • M.D., 2017, Texas Tech University Health Sciences Center (Lubbock)
  • Residency

    • Intern and Resident, Internal Medicine, Louisiana State University Health Sciences Central/Oschner Health System 2020
  • Fellowship

    • Infectious Diseases – Immunocompromised track, University of Texas Health Sciences Center (Houston) & MD Anderson Cancer Center, 2022
    • Training Program for Antimicrobial Resistance T32, Houston Methodist Hospital/Houston Methodist Research Institute, 2023
  • Certifications

    • American Board of Internal Medicine Board Certification, 2020
    • American Board of Internal Medicine, Infectious Disease Board Certification, 2022

Areas of interest

  • Pseudomonas aeruginosa pathogenicity and resistance mechanisms
  • Immunocompromised host bacterial pathogens
  • Enterococcus faecalis anti-microbial resistance
  • Optimization of novel cephalosporin use
  • Antimicrobial stewardship


Elsevier pure profile

Selected publications

  • Egge, Stephanie L., James S. Lewis, and Morgan Hakki. "Case Commentary: Successful Use of Cefepime/Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia." Antimicrobial Agents and Chemotherapy (2023): e00663-23.
  • Shropshire, William C., Bradley T. Endres, Jovan Borjan, Samuel L. Aitken, William C. Bachman, Christi L. McElheny, Chin-Ting Wu, Stephanie L. Egge et al. "High-level ceftazidime-avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated beta-lactamase CMY-185 variant."  Journal of Antimicrobial Chemotherapy,(2023).
  • Egge, Stephanie L., Apoorva Cheeti, and Samina Hayat. "Acute human immunodeficiency virus infection associated hemophagocytic lymphohistiocytosis." IDCases 21 (2020): e00861.
  • Egge, Stephanie, Eric Wei, Erin Clements, and Andrew Stevenson Joel Chandranesan. "Post-traumatic fatal disseminated Apophysomyces elegans infection." Medical mycology case reports 22 (2018): 45-47
  • Lin, Jean Z., Alexandro J. Martagón, Stephanie L. Cimini, Daniel D. Gonzalez, David W. Tinkey, Amadeo Biter, John D. Baxter et al. "Pharmacological activation of thyroid hormone receptors elicits a functional conversion of white to brown fat." Cell reports 13, no. 8 (2015): 1528-1537.
  • Martagón, Alexandro J., Jean Z. Lin, Stephanie L. Cimini, Paul Webb, and Kevin J. Phillips. "The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice." PLoS One 10, no. 4 (2015): e0122987